Endometrial Cryoablation for the Treatment of Heavy Menstrual Bleeding: 36-Month Outcomes from the CLARITY Study

Howard L Curlin, Ted L Anderson, Howard L Curlin, Ted L Anderson

Abstract

Study objective: To examine long-term outcomes from the pivotal study that evaluated the safety and effectiveness of the Cerene® Cryotherapy Device (Channel Medsystems, Berkeley, CA) in premenopausal women with heavy menstrual bleeding due to benign causes who have completed childbearing.

Methods: The prospective, multicenter, single-arm, open-label study had eight sites in the USA, one in Mexico, and two in Canada. Inclusion criteria included uterine sound ≤10 cm, endometrial cavity length 2.5 to 6.5 cm, age 25 to 50 years, a pictorial blood loss assessment chart score of ≥150, no submucosal myomata and/or uterine obstruction, distortion, or abnormality. A total of 242 subjects underwent a 2.5-minute cryoablation. Long-term follow-up visits were conducted at Month 24 and Month 36. Data collected included gynecological adverse events, description of last menstrual period, contraception status, self-report of pregnancy, medical or surgical interventions to treat abnormal uterine bleeding, satisfaction, recommendation, and quality of life (QoL). QoL outcomes were measured with the Menorrhagia Impact Questionnaire (MIQ) and the Premenstrual Symptoms Impact Survey (PMSIS™).

Results: 201 subjects completed their Month 36 final study visit. Subject outcomes were comparable to those at Month 12. Eighty-nine percent of subjects reported amenorrhea, a lighter-than-normal, or normal period, 91% of subjects had no or slight limitations in MIQ measured activities, and 85% reported premenstrual symptoms at a low frequency. Eighty-five percent of the subjects were satisfied or very satisfied. The cumulative incidence of hysterectomy was 5% and reintervention was 8.7%. Forty-nine gynecologic adverse events (AE) were reported; one non-serious AE, postcoital bleeding, was reported as related to the procedure. No serious device-related or procedure-related AEs were reported.

Conclusion: Study data demonstrate that the positive effects of Cerene Cryotherapy Device treatment are sustained through Month 36 and that the risks associated with the device and procedure are low (ClinicalTrials.gov; NCT02842736).

Keywords: ablation; cryotherapy; endometrial; menorrhagia.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2022 Curlin and Anderson.

Figures

Figure 1
Figure 1
Subject satisfaction with cerene treatment outcome and willingness to recommend.
Figure 2
Figure 2
MIQ: Impact of heavy menstrual bleeding on work, physical, social/leisure activities.
Figure 3
Figure 3
PMSIS: Incidence and severity of premenstrual symptoms.

References

    1. Centers Disease Control Prevention. Heavy menstrual bleeding. Centers for disease control and prevention; 2015. Available from: . Accessed August 4, 2022.
    1. Hurskainen R, Grenman S, Komi I, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand. 2007;86(6):749–757. doi:10.1080/00016340701415400
    1. Su S, Yang X, Su Q, Zhao Y. Prevalence and knowledge of heavy menstrual bleeding among gynecology outpatients by scanning a WeChat QR Code. PLoS One. 2020;15(4):e0229123. doi:10.1371/journal.pone.0229123
    1. Santer M, Wyke S, Warner P. Women’s management of menstrual symptoms: findings from a postal survey and qualitative interviews. Soc Sci Med. 2008;66(2):276–288. doi:10.1016/j.socscimed.2007.08.018
    1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194. doi:10.1111/j.1524-4733.2007.00168.x
    1. Jensen JT, Lefebvre P, Laliberté F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Women's Health. 2012;21(5):539–547. doi:10.1089/jwh.2011.3147
    1. Levie MD, Chudnoff SG, Prospective A. Multicenter, pivotal trial to evaluate the safety and effectiveness of the AEGEA vapor endometrial ablation system. J Minim Invasive Gynecol. 2019;26(4):679–687. doi:10.1016/j.jmig.2018.07.012
    1. Cooper J, Gimpelson R, Laberge P, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9(4):418–428. doi:10.1016/S1074-3804(05)60513-0
    1. Munro MG. Endometrial ablation. Best Pract Res Clin Obstet Gynaecol. 2018;46:120–139. doi:10.1016/j.bpobgyn.2017.10.003
    1. Wortman M. Late-onset endometrial ablation failure. Case Rep Women's Health. 2017;12(15):11–28. doi:10.1016/j.crwh.2017.07.001
    1. Klebanoff J, Makai GE, Patel NR, Hoffman MK. Incidence and predictors of failed second-generation endometrial ablation. Gynecol Surg. 2017;14(1):26. doi:10.1186/s10397-017-1030-4
    1. Wortman M, Cholkeri A, McCausland AM, McCausland VM. Late-onset endometrial ablation failure–etiology, treatment, and prevention. J Minim Invasive Gynecol. 2015;22(3):323–331. doi:10.1016/j.jmig.2014.10.020
    1. Cooper K, Breeman S, Scott NW, et al.; HEALTH Study Group. Laparoscopic supracervical hysterectomy versus endometrial ablation for women with heavy menstrual bleeding (HEALTH): a parallel-group, open-label, randomised controlled trial. Lancet. 2019;394(10207):1425–1436. doi:10.1016/S0140-6736(19)31790-8
    1. Leyland N, Harris M. Water vapor endometrial ablation for heavy menstrual bleeding: 36-month follow-up of a prospective, multicenter pivotal clinical trial. Int J Women's Health. 2021;13:169–176. doi:10.2147/IJWH.S279864
    1. McCausland A, McCausland V. Long-term complications of endometrial ablation: cause, diagnosis, treatment, and prevention. J Minim Invasive Gynecol. 2007;14:399–406. doi:10.1016/j.jmig.2007.04.004
    1. Ahonkallio SJ, Liakka AK, Martikainen HK, et al. Feasibility of endometrial assessment after thermal ablation.”. Euro J Obstet Gynec Reprod Biol. 2009;147:69–71. doi:10.1016/j.ejogrb.2009.06.014
    1. Luo X, Lim C, Li L, et al. Hysteroscopic appearance of endometrial cavity after microwave endometrial ablation. J Minim Invasive Gynecol. 2010;17:30–36. doi:10.1016/j.jmig.2009.09.012
    1. MacMahon C, Hatti A, Bakour S, et al. Challenges of endometrial assessment after ablation in women with postmenopausal bleeding - A case series. Obstet Gynecol. 2018;38(3):432–434.
    1. Wortman M, Daggett A, Deckman A. Ultrasound-guided reoperative hysteroscopy for managing global endometrial ablation failures. J Min Invasive Gynecol. 2014;21(2):238–244. doi:10.1016/j.jmig.2013.09.011
    1. Cerene®. Cryotherapy Device Instructions for Use. Berkeley, CA: Channel Medsystems; 2019.
    1. Curlin HL, Cintron LC, Anderson TL, Prospective A. Multicenter, clinical trial evaluating the safety and effectiveness of the cerene device to treat heavy menstrual bleeding. J Minim Invasive Gynecol. 2021;28(4):899–908. doi:10.1016/j.jmig.2020.08.013
    1. Evans PJ. Cryoanalgesia. The application of low temperatures to nerves to produce anaesthesia or analgesia. Anaesthesia. 1981;36(11):1003–1013. doi:10.1111/j.1365-2044.1981.tb08673.x
    1. FDA. Letter to endometrial ablation industry about objective performance criteria. Available from: . Accessed December 14, 2021.
    1. Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010;26(12):2745–2755. doi:10.1185/03007995.2010.532200
    1. Wallenstein GV, Blaisdell-Gross B, Gajria K, et al. Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J Women's Health. 2008;17(3):439–450. doi:10.1089/jwh.2007.0377
    1. Sharp HT. Endometrial ablation: postoperative complications. Am J Obstet Gynecol. 2012;207(4):242–247. doi:10.1016/j.ajog.2012.04.011
    1. Longinotti MK, Jacobson GF, Hung YY, Learman LA. Probability of hysterectomy after endometrial ablation. Obstet Gynecol. 2008;112(6):1214–1220. doi:10.1097/AOG.0b013e31818c1766
    1. Shavell VI, Diamond MP, Senter JP, Kruger ML, Johns DA. Hysterectomy subsequent to endometrial ablation. J Minim Invasive Gynecol. 2012;19(4):459–464. doi:10.1016/j.jmig.2012.03.013
    1. Talukdar S, Eisenstein D, Sangha R. Symptomatic central hematometra and postablation tubal sterilization syndrome (PATSS) after second generation endometrial ablation. J Minim Invasive Gynecol. 2015;22(6S):S189. doi:10.1016/j.jmig.2015.08.689
    1. Hubert SR, Marcus PS, Rothenberg JM, Schilder JM, Hurd WW. Hematometra after thermal balloon endometrial ablation in a patient with cervical incompetence. J Laparoendosc Adv Surg Tech A. 2001;11(5):311–313. doi:10.1089/109264201317054627
    1. Sinha P. Endometrial ablation–long-term complications. Wiad Lek. 2004;57(Suppl 1):276–277.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться